David Amsellem
Stock Analyst at Piper Sandler
(4.78)
# 132
Out of 4,996 analysts
152
Total ratings
65%
Success rate
23.52%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SUPN Supernus Pharmaceuticals | Maintains: Neutral | $36 → $40 | $47.01 | -14.91% | 16 | Aug 29, 2025 | |
| AMGN Amgen | Maintains: Overweight | $328 → $342 | $272.98 | +25.28% | 5 | Aug 25, 2025 | |
| BIIB Biogen | Maintains: Neutral | $115 → $118 | $137.37 | -14.10% | 2 | Aug 14, 2025 | |
| ABBV AbbVie | Assumes: Overweight | $231 | $220.61 | +4.71% | 1 | Aug 12, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $30 → $25 | $26.84 | -6.86% | 9 | Aug 8, 2025 | |
| CORT Corcept Therapeutics | Maintains: Overweight | $131 → $121 | $83.87 | +44.27% | 8 | Aug 1, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $154 → $175 | $142.00 | +23.24% | 11 | Jul 31, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $24 → $18 | $10.21 | +76.30% | 6 | May 15, 2025 | |
| COLL Collegium Pharmaceutical | Reiterates: Neutral | $36 → $37 | $34.41 | +7.53% | 8 | May 9, 2025 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $176 → $147 | $127.00 | +15.75% | 14 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $65 | $44.12 | +47.33% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3 → $4 | $8.18 | -51.10% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $13 | $23.92 | -45.65% | 5 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $10 | $9.52 | +5.04% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $30 | $18.34 | +63.58% | 10 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $13 | $15.34 | -15.25% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $11 | $9.75 | +12.82% | 4 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 → $37 | $27.89 | +32.66% | 7 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $93.05 | -26.92% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $6.48 | -53.70% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $25.24 | +66.40% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $5.99 | +66.94% | 1 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $1.39 | +1,410.79% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $113 | $116.76 | -3.22% | 3 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $27.51 | +52.67% | 3 | Oct 16, 2023 |
Supernus Pharmaceuticals
Aug 29, 2025
Maintains: Neutral
Price Target: $36 → $40
Current: $47.01
Upside: -14.91%
Amgen
Aug 25, 2025
Maintains: Overweight
Price Target: $328 → $342
Current: $272.98
Upside: +25.28%
Biogen
Aug 14, 2025
Maintains: Neutral
Price Target: $115 → $118
Current: $137.37
Upside: -14.10%
AbbVie
Aug 12, 2025
Assumes: Overweight
Price Target: $231
Current: $220.61
Upside: +4.71%
Amphastar Pharmaceuticals
Aug 8, 2025
Maintains: Neutral
Price Target: $30 → $25
Current: $26.84
Upside: -6.86%
Corcept Therapeutics
Aug 1, 2025
Maintains: Overweight
Price Target: $131 → $121
Current: $83.87
Upside: +44.27%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Overweight
Price Target: $154 → $175
Current: $142.00
Upside: +23.24%
Organon & Co.
May 15, 2025
Maintains: Overweight
Price Target: $24 → $18
Current: $10.21
Upside: +76.30%
Collegium Pharmaceutical
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $34.41
Upside: +7.53%
Jazz Pharmaceuticals
May 7, 2025
Reiterates: Overweight
Price Target: $176 → $147
Current: $127.00
Upside: +15.75%
Apr 22, 2025
Initiates: Overweight
Price Target: $65
Current: $44.12
Upside: +47.33%
Mar 7, 2025
Reiterates: Neutral
Price Target: $3 → $4
Current: $8.18
Upside: -51.10%
Mar 6, 2025
Maintains: Overweight
Price Target: $16 → $13
Current: $23.92
Upside: -45.65%
Mar 5, 2025
Reiterates: Neutral
Price Target: $14 → $10
Current: $9.52
Upside: +5.04%
Jan 17, 2025
Maintains: Overweight
Price Target: $23 → $30
Current: $18.34
Upside: +63.58%
Jan 10, 2025
Maintains: Overweight
Price Target: $24 → $13
Current: $15.34
Upside: -15.25%
Nov 11, 2024
Maintains: Overweight
Price Target: $9 → $11
Current: $9.75
Upside: +12.82%
Oct 25, 2024
Reiterates: Overweight
Price Target: $38 → $37
Current: $27.89
Upside: +32.66%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $93.05
Upside: -26.92%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $6.48
Upside: -53.70%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $25.24
Upside: +66.40%
Apr 11, 2024
Initiates: Overweight
Price Target: $10
Current: $5.99
Upside: +66.94%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $1.39
Upside: +1,410.79%
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $116.76
Upside: -3.22%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $27.51
Upside: +52.67%